Analysts Set Bio-Rad Laboratories, Inc. (NYSE:BIO) PT at $333.50

Key Points

• Bio-Rad Laboratories, Inc. has received an average rating of “Moderate Buy” from analysts, with price targets ranging from $265.00 to $409.00 based on various research reports.
• Institutional investors have significantly increased their stakes in Bio-Rad, with First Eagle Investment Management increasing its holdings by 60.7% in the second quarter.
• The company's recent earnings report showed an EPS of $2.61, surpassing estimates, with revenue of $651.60 million for the quarter, reflecting a 2.1% increase year-over-year.

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $333.50.

Several analysts have weighed in on BIO shares. Wall Street Zen cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, August 22nd. Royal Bank Of Canada boosted their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Wells Fargo & Company boosted their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Finally, Zacks Research raised shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th.

Institutional Investors Weigh In On Bio-Rad Laboratories

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its position in shares of Bio-Rad Laboratories by 3,633.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company's stock valued at $27,000 after acquiring an additional 109 shares during the period. Quarry LP bought a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $29,000. Curat Global LLC bought a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $34,000. Geneos Wealth Management Inc. grew its position in shares of Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. Finally, Allworth Financial LP grew its position in shares of Bio-Rad Laboratories by 260.0% during the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock valued at $36,000 after acquiring an additional 104 shares during the period. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Trading Up 1.6%

Shares of NYSE:BIO traded up $4.72 on Thursday, reaching $298.39. 199,920 shares of the company traded hands, compared to its average volume of 249,221. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $8.07 billion, a P/E ratio of 25.44 and a beta of 0.95. Bio-Rad Laboratories has a 52 week low of $211.43 and a 52 week high of $387.99. The business's 50-day simple moving average is $263.60 and its 200 day simple moving average is $251.14.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.68. The company had revenue of $651.60 million for the quarter, compared to analysts' expectations of $614.82 million. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.Bio-Rad Laboratories's quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Bio-Rad Laboratories will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.